Non-Enrolling and High-Enrolling Site Data
Applied Clinical Trials
Medidata Solutions
Site performance is a critical factor in the success of any clinical trial. Sponsors are continually looking for ways to better track site performance and minimize the number of sites that fail to enroll a patient. To that end, Medidata has tracked two metrics related to the performance of investigative sites, the percentages of both non-enrolling and high-enrolling sites. A non-enrolling site is a site that actively participated in a clinical trial but failed to recruit any patients.
Nearly one-third of sites performing clinical trials never enroll a single patient.
Non-enrolling sites contribute significantly to both study delays and unnecessary costs. Drawn from the more than 2,000 studies in the Medidata InsightsTM metric warehouse, the non-enrolling site performance metric shown in the graph illustrates that nearly one-third of sites performing clinical trials never enroll a single patient. While Asia Pacific is clearly the best performing geographic region at just more than 17%, in certain geographies the percentage is over 40%.
At tens of thousands of dollars in site initiation and maintenance costs per site, wouldn't it be nice to be able to eliminate or at least reduce the number of non-productive sites? What can be done to drive better site selection and performance? We'd love to hear your take on these results.
Please continue to stay tuned as we look further into Insights data throughout 2012.
—Medidata Solutions, www.mdsol.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
